Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib + topotecan + temozolomide in pediatric relapsed/refractory neuroblastoma and solid tumors
NCT05429502Phase 1Terminated
- Sponsor
- Novartis
- Start
- Dec 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of ribociclib in neuroblastoma, medulloblastoma, glioma and 2 more, sponsored by Novartis. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Dec 2022; status: terminated.
02
Drugs
ribociclib
03
Conditions
neuroblastomamedulloblastomagliomamalignant rhabdoid tumor (MRT)rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT05429502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429502.